These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 2170526)
1. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. Baloch Z; Cohen S; Coffman FD J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526 [TBL] [Abstract][Full Text] [Related]
2. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Utsugi T; Mattern MR; Mirabelli CK; Hanna N Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396 [TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity mediated by tumor necrosis factor in variant subclones of the ME-180 cervical carcinoma line: modulation by specific inhibitors of DNA topoisomerase II. Coffman FD; Green LM; Godwin A; Ware CF J Cell Biochem; 1989 Feb; 39(2):95-105. PubMed ID: 2541144 [TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity. Utsugi T; Demuth S; Hanna N Cancer Res; 1989 Mar; 49(6):1429-33. PubMed ID: 2538225 [TBL] [Abstract][Full Text] [Related]
5. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Holm C; Covey JM; Kerrigan D; Pommier Y Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254 [TBL] [Abstract][Full Text] [Related]
6. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Bowman KJ; Newell DR; Calvert AH; Curtin NJ Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322 [TBL] [Abstract][Full Text] [Related]
8. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Alexander RB; Nelson WG; Coffey DS Cancer Res; 1987 May; 47(9):2403-6. PubMed ID: 2436763 [TBL] [Abstract][Full Text] [Related]
9. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008 [TBL] [Abstract][Full Text] [Related]
10. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Goldwasser F; Bae I; Fornace AJ; Pommier Y Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795 [TBL] [Abstract][Full Text] [Related]
11. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Lelièvre S; Benchokroun Y; Larsen AK Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278 [TBL] [Abstract][Full Text] [Related]
12. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity. Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831 [TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Wolverton JS; Danks MK; Granzen B; Beck WT Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239 [TBL] [Abstract][Full Text] [Related]
14. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Robson CN; Hoban PR; Harris AL; Hickson ID Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220 [TBL] [Abstract][Full Text] [Related]
15. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151 [TBL] [Abstract][Full Text] [Related]
16. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis. Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621 [TBL] [Abstract][Full Text] [Related]
18. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. Kerrigan D; Pommier Y; Kohn KW NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238 [TBL] [Abstract][Full Text] [Related]
19. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377 [TBL] [Abstract][Full Text] [Related]
20. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Chen M; Beck WT Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]